Larry E. Fields

3.4k citations

33 papers · 2.9k · 2 hit papers · h-index 17

Impact in

Internal Medicine top 2%
- Venous Thromboembolism Diagnosis and Management
Cardiology and Cardiovascular Medicine top 2%
- Blood Pressure and Hypertension Studies
- Atrial Fibrillation Management and Outcomes

Papers in

Cardiology and Cardiovascular Medicine 17
- Atrial Fibrillation Management and Outcomes 8
- Antiplatelet Therapy and Cardiovascular Diseases 5
- Blood Pressure and Hypertension Studies 3
Internal Medicine 5
- Venous Thromboembolism Diagnosis and Management 5

Co-authors: Edward J. Roccella (2 shared papers)Paul D. Sorlie (2 shared papers)Vicki L. Burt (1 shared paper)Thomas Thom (1 shared paper)MICHAEL M. WOLZ (1 shared paper)Jeffrey A. Cutler (1 shared paper)Dennis Y. Loh (5 shared papers)Keiko Nakayama (2 shared papers)
Journals: Hypertension (3 papers)Current Medical Research and Opinion (2 papers)Proceedings of the National Academy of Sciences (2 papers)The Journal of Immunology (2 papers)Thrombosis Research (2 papers)
Partner nations: United States Belgium Italy

In The Last Decade

Larry E. Fields

32 papers receiving 2.7k citations

Larry E. Fields's Hit Papers

align trajectories log scale

Trends in Hypertension Prevalence, Awareness, Treatment, and Control Rates in United States Adults Between 1988–1994 and 1999–2004 2008 · 751 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2008 Hypertension
2004 Hypertension

Peers

Countries citing papers authored by Larry E. Fields

Since Specialization

Citations

This map shows the geographic impact of Larry E. Fields's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry E. Fields with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry E. Fields more than expected).

Fields of papers citing papers by Larry E. Fields

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larry E. Fields. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry E. Fields. The network helps show where Larry E. Fields may publish in the future.

Co-authors

The 25 scholars most cited alongside Larry E. Fields, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Larry E. Fields Line = papers co-authored together Larry E. Fields links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	The Burden of Adult Hypertension in the United States 1999 to 2000 Hypertension ·Larry E. Fields, Vicki L. Burt, Jeffery A. Cutler, Jeffrey Hughes, Edward J. Roccella, Paul D. Sorlie Hit paper breakdown →	2004	769
2	Trends in Hypertension Prevalence, Awareness, Treatment, and Control Rates in United States Adults Between 1988–1994 and 1999–2004 Hypertension ·Jeffrey A. Cutler, Paul D. Sorlie, MICHAEL M. WOLZ, Thomas Thom, Larry E. Fields, Edward J. Roccella Hit paper breakdown →	2008	751
3	Disappearance of the Lymphoid System in Bcl-2 Homozygous Mutant Chimeric Mice Science ·Kei-ichi Nakayama, Keiko Nakayama, Izumi Negishi, Keisuke Kuida, Yoichi Shinkai, Marjorie C. Louie, Larry E. Fields, Phillip J. Lucas	1993	371
4	Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. The Journal of Immunology ·Philip J. Lucas, Izumi Negishi, Keiko Nakayama, Larry E. Fields, Dennis Y. Loh	1995	194
5	Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban Clinical Cardiology ·Sally G. Tamayo, W. Frank Peacock, Manesh R. Patel, Nicholas Sicignano, Kathleen Pillsbury Hopf, Larry E. Fields, Troy C. Sarich, Shujian Wu	2015	133
6	Mutations of the chloramphenicol acetyl transferase transgene driven by the immunoglobulin promoter and intron enhancer International Immunology ·Takachika Azuma, Noboru Motoyama, Larry E. Fields, Dennis Y. Loh	1993	69
7	Expression of Janus Kinase 3 in Human Endothelial and Other Non-lymphoid and Non-myeloid Cells Journal of Biological Chemistry ·James W. Verbsky, Erika A Bach, Yifu Fang, Liping Yang, David A. Randolph, Larry E. Fields	1996	68
8	Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke International Journal of Cardiology ·Mark J. Alberts, W. Frank Peacock, Larry E. Fields, Thomas J. Bunz, Elaine Nguyen, Dejan Milentijevic, Jeff R. Schein, Craig Ian Coleman	2016	57
9	Impact of Co-morbidities and Patient Characteristics on International Normalized Ratio Control Over Time in Patients With Nonvalvular Atrial Fibrillation The American Journal of Cardiology ·Winnie W. Nelson, Jiyoon C. Choi, Julie Vanderpoel, Chandrasekharra V. Damaraju, Peter Wildgoose, Larry E. Fields, Jeffrey R Schein	2013	51
10	Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population Thrombosis Research ·Charles Edward Mahan, Maxine D. Fisher, Roger M. Mills, Larry E. Fields, Judith J. Stephenson, An-Chen Fu, Alex C. Spyropoulos	2013	50
11	One-Year Adherence to Warfarin Treatment for Venous Thromboembolism in High-Risk Patients and Its Association with Long-term Risk of Recurrent Events Journal of Managed Care Pharmacy ·Shih‐Yin Chen, Ning Wu, Michael P. Gulseth, Joyce C. LaMori, Brahim Bookhart, Luke Boulanger, Larry E. Fields, Jeff R. Schein	2013	50
12	Dysregulated Myelopoiesis in Mice Lacking Jak3 Blood ·William J. Grossman, James W. Verbsky, Liping Yang, Leslie J. Berg, Larry E. Fields, David Chaplin, Lee Ratner	1999	43
13	Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube Clinical Pharmacology in Drug Development ·Kenneth Todd Moore, Mark A. Krook, Seema Vaidyanathan, Troy C. Sarich, ChandrasekharRao Venkata Damaraju, Larry E. Fields	2014	40
14	Organ injury associated with extrathymic induction of immune tolerance in doubly transgenic mice. Proceedings of the National Academy of Sciences ·Larry E. Fields, Dennis Y. Loh	1992	34
15	International Normalized Ratio Stability in Warfarin-Experienced Patients with Nonvalvular Atrial Fibrillation American Journal of Cardiovascular Drugs ·Winnie W. Nelson, Sunita M Desai, ChandrasekharRao Venkata Damaraju, Lang Lu, Larry E. Fields, Peter Wildgoose, Jeffery R. Schein	2015	34
16	Coronary thrombolysis with facilitated absorption of intramuscularly injected tissue-type plasminogen activator. Proceedings of the National Academy of Sciences ·Burton E. Sobel, Larry E. Fields, Alice K. Robison, Keith A.A. Fox, Stanley J. Sarnoff	1985	27
17	Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials Current Medical Research and Opinion ·Elaine Nguyen, Charles Michael White, Manesh R. Patel, Larry E. Fields, W. Frank Peacock, Concetta Crivera, Craig Ian Coleman	2016	27
18	Effect of fatty acid on performance and lipid content of hearts from diabetic rabbits American Journal of Physiology-Heart and Circulatory Physiology ·Larry E. Fields, Alan Daugherty, Steven R. Bergmann	1986	17
19	International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation Current Medical Research and Opinion ·Winnie W. Nelson, Sunita M Desai, C.V. Damaraju, Lang Lu, Larry E. Fields, Peter Wildgoose, Jeff R. Schein	2014	16
20	Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation Journal of Interventional Cardiac Electrophysiology ·Gerald V. Naccarelli, Riccardo Cappato, Stefan Hans Hohnloser, Francis E. Marchlinski, David J. Wilber, Jim X. Xiang, Changsheng Ma, Susanne Hess	2014	15

About Larry E. Fields

Larry E. Fields is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine, Immunology, Nutrition and Dietetics and Hematology, having authored 33 papers that have together received 2.9k indexed citations. Recurring topics across this work include Atrial Fibrillation Management and Outcomes (8 papers), Antiplatelet Therapy and Cardiovascular Diseases (5 papers), Venous Thromboembolism Diagnosis and Management (5 papers), T-cell and B-cell Immunology (5 papers), Immune Cell Function and Interaction (4 papers), Blood Pressure and Hypertension Studies (3 papers), Sodium Intake and Health (3 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Internal Medicine (207 citations), Cardiology and Cardiovascular Medicine (1.2k citations), Family Practice (54 citations), Immunology (523 citations) and Nutrition and Dietetics (213 citations). Larry E. Fields has collaborated with scholars based in United States, Belgium and Italy. Frequent co-authors include Edward J. Roccella, Paul D. Sorlie, Vicki L. Burt, Thomas Thom, MICHAEL M. WOLZ, Jeffrey A. Cutler, Dennis Y. Loh, Keiko Nakayama, Izumi Negishi and Philip J. Lucas. Their work appears in journals such as Hypertension, Current Medical Research and Opinion, Proceedings of the National Academy of Sciences, The Journal of Immunology and Thrombosis Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Larry E. Fields

Impact in

Papers in i

In The Last Decade

Larry E. Fields

Larry E. Fields's Hit Papers

Peers

Countries citing papers authored by Larry E. Fields

Fields of papers citing papers by Larry E. Fields

All Works

About Larry E. Fields

Explore authors with similar magnitude of impact

Papers in